Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Mark

Showing results (1-10 of 83) with videos related to

Pageof 9
Sort By:
Idrugs : the Investigational Drugs Journal|June 6, 2003
NN-2211 Novo NordiskMichael Mark
Pharmazie in Unserer Zeit|June 20, 2002
[The chemotherapeutic use of antidiabetics. Sulfonylurea compounds and glinides]Michael Mark
Therapeutische Umschau. Revue Therapeutique|October 2, 2010
[New treatments of malignant lymphoma--a review]Michael Mark, Thomas Cerny
Medical Oncology (Northwood, London, England)|June 14, 2011
Fatal pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remissionMichael Mark, Beat Thürlimann
Physical Review. E|May 20, 2020
Robust identification of controlled Hawkes processesMichael Mark, Thomas A Weber
The Journal of Pharmacology and Experimental Therapeutics|October 31, 2008
Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent modelsLeo Thomas, Moh Tadayyon, Michael Mark
Diabetes Care|December 8, 2016
Response to Comment on Ferrannini et al. Diabetes Care 2016;39:1108-1114. Comment on Mudaliar et al. Diabetes Care 2016;39:1115-1122Ele Ferrannini, Michael Mark, Eric Mayoux
Diabetes Care|November 24, 2016
Response to Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care 2016;39:1108-1114Ele Ferrannini, Michael Mark, Eric Mayoux
Diabetes Care|June 12, 2016
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" HypothesisEle Ferrannini, Michael Mark, Eric Mayoux
Lung Cancer (Amsterdam, Netherlands)|July 22, 2016
Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: Report of two casesYannis Metaxas, Richard Cathomas, Michael Mark, et al.
Pageof 9

Showing results (1-10 of 83) with videos related to

Sort By:
Pageof 9
Idrugs : the Investigational Drugs Journal|June 6, 2003
NN-2211 Novo NordiskMichael Mark
Pharmazie in Unserer Zeit|June 20, 2002
[The chemotherapeutic use of antidiabetics. Sulfonylurea compounds and glinides]Michael Mark
Therapeutische Umschau. Revue Therapeutique|October 2, 2010
[New treatments of malignant lymphoma--a review]Michael Mark, Thomas Cerny
Medical Oncology (Northwood, London, England)|June 14, 2011
Fatal pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remissionMichael Mark, Beat Thürlimann
Physical Review. E|May 20, 2020
Robust identification of controlled Hawkes processesMichael Mark, Thomas A Weber
The Journal of Pharmacology and Experimental Therapeutics|October 31, 2008
Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent modelsLeo Thomas, Moh Tadayyon, Michael Mark
Diabetes Care|December 8, 2016
Response to Comment on Ferrannini et al. Diabetes Care 2016;39:1108-1114. Comment on Mudaliar et al. Diabetes Care 2016;39:1115-1122Ele Ferrannini, Michael Mark, Eric Mayoux
Diabetes Care|November 24, 2016
Response to Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care 2016;39:1108-1114Ele Ferrannini, Michael Mark, Eric Mayoux
Diabetes Care|June 12, 2016
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" HypothesisEle Ferrannini, Michael Mark, Eric Mayoux
Lung Cancer (Amsterdam, Netherlands)|July 22, 2016
Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: Report of two casesYannis Metaxas, Richard Cathomas, Michael Mark, et al.
Pageof 9